About this trial
Atrial fibrillation (AF) is the most common rhythm disturbance of the heart. It can affect people of any age but usually happens as we get older. It can cause palpitations, breathlessness, lethargy, and fainting attacks. It is also associated with an increased risk of strokes.
The best treatment for it at the moment involves burning or freezing (ablation) the heart muscle in a part of the heart called the left atrium. The ablation injures the heart muscle around the so-called pulmonary veins and the procedure is called a 'pulmonary vein isolation'. This procedure work in about 60% of people.
The study team have found that there are nerve endings in the heart that also cause AF and have shown that ablating these nerve endings also prevents AF. These Nerve endings are known as ganglionated plexuses (GPs).
The study team would now like to perform a trial in people who still have AF after the usual pulmonary vein procedure. The study team hope that ablating the nerve endings that cause AF (GPs), we will stop their AF coming back. The study team will compare this procedure to the normal approach of doing the pulmonary vein isolation again
Eligibility criteria
Qualifiers
Males or females from 18 to 85yrs old
Symptomatic paroxysmal atrial fibrillation
Suitable candidate for catheter ablation
Signed informed consent
Disqualifiers
Contraindication to catheter ablation
Contraindication for general anaesthetic
Presence of a left ventricular thrombus
Valvular disease that is grade moderate or greater
Trial design
Treatments tested in this trial
- Right Atrial ganglionated plexus ablation
- Holter Monitor
- Pulmonary vein isolation
- Right cavo-tricuspid and left roof linear ablation
- Personal ECG recordings
- Quality of life questionnaire